Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding study of XY03-EA tablets in acute ischemic stroke
CTR20221968Phase 2Active
- Sponsor
- Yiling Pharmaceutical
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XY03-EA in ischemic stroke, sponsored by Yiling Pharmaceutical. Started Sep 2022; status: active.
02
Drugs
XY03-EA
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20221968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221968.